METHODS AND DEVICES FOR ADMINISTRATION OF SUBSTANCES INTO THE INTRADERMAL LAYER OF SKIN FOR SYSTEMIC ABSORPTION

Abstract: Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption.
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
METHODS AND DEVICES FOR ADMINISTRATION OF SUBSTANCES INTO THE INTRADERMAL LAYER OF SKIN FOR SYSTEMIC ABSORPTION

FIELD OF THE INVENTION

[0001] The present invention relates to methods and devices for administration of substances into the intradermal layer of skin for systemic absorption.

BACKGROUND OF THE INVENTION

[0002] The importance of efficiently and safely administering pharmaceutical substances such as diagnostic agents and drugs has long been recognized. Although an important consideration for all pharmaceutical substances, obtaining adequate bioavailability of large molecules such as proteins that have arisen out of the biotechnology industry has recently highlighted this need to obtain efficient and reproducible absorption (Cleland et al., Curr. Opin. Biotechnol. 12: 212-219, 2001). The use of conventional needles has long provided one approach for delivering pharmaceutical substances to humans and animals by administration through the skin. Considerable effort has been made to achieve reproducible and efficacious delivery through the skin while improving the ease of injection and reducing patient apprehension and/or pain associated with conventional needles. Furthermore, certain delivery systems eliminate needles entirely, and rely upon chemical mediators or external driving forces such as iontophoretic currents or thermal poration or sonophoresis to breach the stratum corneum, the outermost layer of the skin, and deliver substances through the surface of the skin. However, such delivery systems do not reproducibly breach the skin barriers or deliver the pharmaceutical substance to a given depth below the surface of the skin and consequently, clinical results can be variable. Thus, mechanical breach of the stratum corneum such as with needles, is believed to provide the most reproducible method of administration of substances through the surface of the skin, and to provide control and reliability in placement of administered substances.
[0003] Approaches for delivering substances beneath the surface of the skin have almost exclusively involved transdermal administration, i.e. delivery of substances through the skin to a site beneath the skin. Transdermal delivery includes subcutaneous, intramuscular or intravenous routes of administration of which, intramuscular (IM) and subcutaneous (SC) injections have been the most commonly used.

[0004] Anatomically, the outer surface of the body is made up of two major tissue layers, an outer epidermis and an underlying dermis, which together constitute the skin (for review, see Physiology, Biochemistry, and Molecular Biology of the Skin, Second Edition, L.A. Goldsmith, Ed., Oxford University Press, New York, 1991). The epidermis is subdivided into five layers or strata of a total thickness of between 75 and 150 μm. Beneath the epidermis lies the dermis, which contains two layers, an outermost portion referred to at the papillary dermis and a deeper layer referred to as the reticular dermis. The papillary dermis contains vast microcirculatory blood and lymphatic plexuses. In contrast, the reticular dermis is relatively acellular and avascular and made up of dense collagenous and elastic connective tissue. Beneath the epidermis and dermis is the subcutaneous tissue, also referred to as the hypodermis, which is composed of connective tissue and fatty tissue. Muscle tissue lies beneath the subcutaneous tissue.

[0005] As noted above, both the subcutaneous tissue and muscle tissue has been commonly used as sites for administration of pharmaceutical substances. The dermis, however, has rarely been targeted as a site for administration of substances, and this may be due, at least in part, to the difficulty of precise needle placement into the intradermal space. Furthermore, even though the dermis, in particular, the papillary dermis has been known to have a high degree of vascularity, it has not heretofore been appreciated that one could take advantage of this high degree of vascularity to obtain an improved absorption profile for administered substances compared to subcutaneous administration. This is because small drug molecules are typically rapidly absorbed after administration
into the subcutaneous tissue, which has been far more easily and predictably targeted than the dermis has been. On the other hand, large molecules such as proteins are typically not well absorbed through the capillary epithelium regardless of the degree of vascularity so that one would not have expected to achieve a significant absorption advantage over subcutaneous administration by the more difficult to achieve intradermal administration even for large molecules.

[0006] One approach to administration beneath the surface to the skin and into the region of the intradermal space has been routinely used in the Mantoux tuberculin test. In this procedure, a purified protein derivative is injected at a shallow angle to the skin surface using a 27 or 30 gauge needle (Flynn et al, *Chest* 106: 1463-5, 1994). A degree of uncertainty in placement of the injection can, however, result in some false negative test results. Moreover, the test has involved a localized injection to elicit a response at the site of injection and the Mantoux approach has not led to the use of intradermal injection for systemic administration of substances.

[0007] Some groups have reported on systemic administration by what has been characterized as "intradermal" injection. In one such report, a comparison study of subcutaneous and what was described as "intradermal" injection was performed (Autret et al, *Therapie* 46:5-8, 1991). The pharmaceutical substance tested was calcitonin, a protein of a molecular weight of about 3600. Although it was stated that the drug was injected intradermally, the injections used a 4 mm needle pushed up to the base at an angle of 60. This would have resulted in placement of the injectate at a depth of about 3.5 mm and into the lower portion of the reticular dermis or into the subcutaneous tissue rather than into the vascularized papillary dermis. If, in fact, this group injected into the lower portion of the reticular dermis rather than into the subcutaneous tissue, it would be expected that the substance would either be slowly absorbed in the relatively less vascular reticular dermis or diffuse into the subcutaneous region to result in what would be functionally the same as subcutaneous administration and absorption. Such actual or functional subcutaneous administration would explain the reported lack of difference between subcutaneous and what was characterized as
intradermal administration, in the times at which maximum plasma concentration was reached, the concentrations at each assay time and the areas under the curves.

[0008] Similarly, Bressolle et al. administered sodium ceftazidime in what was characterized as “intradermal” injection using a 4 mm needle (Bressolle et al. J. Pharm. Sci. 82:1175-1178, 1993). This would have resulted in injection to a depth of 4 mm below the skin surface to produce actual or functional subcutaneous injection, although good subcutaneous absorption would have been anticipated in this instance because sodium ceftazidime is hydrophilic and of relatively low molecular weight.

[0009] Another group reported on what was described as an intradermal drug delivery device (U.S. Patent No. 5,997,501). Injection was indicated to be at a slow rate and the injection site was intended to be in some region below the epidermis, i.e., the interface between the epidermis and the dermis or the interior of the dermis or subcutaneous tissue. This reference, however, provided no teachings that would suggest a selective administration into the dermis nor did the reference suggest any possible pharmacokinetic advantage that might result from such selective administration.

[0010] Thus there remains a continuing need for efficient and safe methods and devices for administration of pharmaceutical substances.

SUMMARY OF THE INVENTION.

[0011] The present disclosure relates to a new parenteral administration method based on directly targeting the dermal space whereby such method dramatically alters the pharmacokinetics (PK) and pharmacodynamics (PD) parameters of administered substances. By the use of direct intradermal (ID) administration means hereafter referred to as dermal-access means, for example, using microneedle-based injection and infusion systems (or other means to accurately target the intradermal space), the pharmacokinetics of many substances including drugs and diagnostic substances, which can be altered when compared
to traditional parental administration routes of subcutaneous and intravenous
delivery. These findings are pertinent not only to microdevice-based injection
means, but other delivery methods such as needleless or needle-free ballistic
injection of fluids or powders into the ID space, Mantoux-type ID injection,
enhanced iontophoresis through microdevices, and direct deposition of fluid,
 solids, or other dosing forms into the skin. Disclosed is a method to increase the
rate of uptake for parenterally-administered drugs without necessitating IV access.
One significant beneficial effect of this delivery method is providing a shorter
$T_{\text{max}}$ (time to achieve maximum blood concentration of the drug). Potential
corollary benefits include higher maximum concentrations for a given unit dose
($C_{\text{max}}$), higher bioavailability, more rapid uptake or absorption rates ($k_{\alpha}$), more
rapid onset of pharmacodynamics or biological effects, and reduced drug depot
effects. According to the present invention, improved pharmacokinetics means
increased bioavailability, decreased lag time ($T_{\text{lag}}$), decreased $T_{\text{max}}$, more rapid
absorption rates, more rapid onset and/or increased $C_{\text{max}}$ for a given amount of
compound administered, compared to subcutaneous, intramuscular or other non-
IV parenteral means of drug delivery.

[0012] By bioavailability ($F$) is meant the fraction or percent of the total
amount of a given dosage that reaches the blood compartment when administered
by a non-IV means relative to an IV administration of the same substance. The
amounts are generally measured as the area under the curve in a plot of
concentration vs. time. By “lag time” ($T_{\text{lag}}$) is meant the delay between the
administration of a compound and time to measurable or detectable blood or
plasma levels. By absorption rate is meant the rate at which a substance is
absorbed from the site of administration and distributed to other parts of the body,
for example, blood, lymph, or tissue. $T_{\text{max}}$ is a value representing the time to
achieve maximal blood concentration of the compound, and $C_{\text{max}}$ is the maximum
blood concentration reached with a given dose and administration method. The
time for onset is a function of $T_{\text{lag}}$, $T_{\text{max}}$ and $C_{\text{max}}$, as all of these parameters
influence the time necessary to achieve a blood (or target tissue) concentration
necessary to realize a biological effect. $T_{\text{max}}$ and $C_{\text{max}}$ can be determined by visual
inspection of graphical results and can often provide sufficient information to
compare two methods of administration of a compound. However, numerical values can be determined more precisely by analysis using kinetic models (as described below) and/or other means known to those of skill in the art.

[0013] Directly targeting the dermal space as taught by the invention provides more rapid onset of effects of drugs and diagnostic substances. The inventors have found that substances can be rapidly absorbed and systemically distributed via controlled ID administration that selectively accesses the dermal vascular and lymphatic microcapillaries, thus the substances may exert their beneficial effects more rapidly than SC administration. This has special significance for drugs requiring rapid onset, such as insulin to decrease blood glucose, pain relief such as for breakthrough cancer pain, or migraine relief, or emergency rescue drugs such as adrenaline or anti-venom. Natural hormones are also released in pulsatile fashion with a rapid onset burst followed by rapid clearance. Examples include insulin that is released in response to biological stimulus, for example high glucose levels. Another example is female reproductive hormones, which are released at time intervals in pulsatile fashion. Human growth hormone is also released in normal patients in a pulsatile fashion during sleep. This benefit allows better therapy by mimicking the natural body rhythms with synthetic drug compounds. Likewise, it may better facilitate some current therapies such as blood glucose control via insulin delivery. Many current attempts at preparing "closed loop" insulin pumps are hindered by the delay period between administering the insulin and waiting for the biological effect to occur. This makes it difficult to ascertain in real-time whether sufficient insulin has been given, without overtitrating and risking hypoglycemia. The more rapid PK/PD of ID delivery eliminates much of this type of problem.

[0014] Mammalian skin contains two layers, as discussed above, specifically, the epidermis and dermis. The epidermis is made up of five layers, the stratum corneum, the stratum lucidum, the stratum granulosum, the stratum spinosum and the stratum germinativum and the dermis is made up of two layers, the upper papillary dermis and the deeper reticular dermis. The thickness of the dermis and epidermis varies from individual to individual, and within an individual, at
different locations on the body. For example, it has been reported that in humans the epidermis varies in thickness from about 40 to about 90 μm and the dermis varies in thickness ranging from just below the epidermis to a depth of from less than 1 mm in some regions of the body to just under 2 to about 4 mm in other regions of the body depending upon the particular study report (Hwang et al., *Ann Plastic Surg* 46:327-331, 2001; Southwood, *Plast. Reconstr. Surg* 15:423-429, 1955; Rushmer et al., *Science* 154:343-348, 1966). The invention herein with respect to administration to humans, encompasses delivery of substances to the dermis at any desired location on the body. Thus the depth of placement of the substance will depend upon the depth of the dermis at the desired location. Such placement may be, for example, from up to about 1 mm in certain instances for abdominal skin (Hwang et al., *supra*) or up to about 4 mm in certain instances for skin of the back (Rushmer et al., *supra*).

[0015] As used herein, intradermal is intended to mean administration of a substance into the dermis in such a manner that the substance readily reaches the richly vascularized papillary dermis and is rapidly absorbed into the blood capillaries and/or lymphatic vessels to become systemically bioavailable. Such can result from placement of the substance in the upper region of the dermis, i.e. the papillary dermis or in the upper portion of the relatively less vascular reticular dermis such that the substance readily diffuses into the papillary dermis. It is believed that placement of a substance predominately at a depth of at least about 0.3 mm, more preferably, at least about 0.4 mm and most preferably at least about 0.5 mm up to a depth of no more than about 2.5 mm, more preferably, no more than about 2.0 mm and most preferably no more than about 1.7 mm will result in rapid absorption of macromolecular and/or hydrophobic substances. Placement of the substance predominately at greater depths and/or into the lower portion of the reticular dermis is believed to result in the substance being slowly absorbed in the less vascular reticular dermis or in the subcutaneous region either of which would result in reduced absorption of macromolecular and/or hydrophobic substances. The controlled delivery of a substance in this dermal space either within the papillary dermis or at the interface between the papillary dermis and reticular dermis or below the papillary dermis in the reticular dermis, but sufficiently above
the interface between the dermis and the subcutaneous tissue, should enable an
efficient (outward) migration of the substance to the (undisturbed) vascular and
lymphatic microcapillary bed (in the papillary dermis), where it can be absorbed
into systemic circulation via these microcapillaries without being sequestered in
transit by any other cutaneous tissue compartment.

[0016] Another benefit of the invention is to achieve more rapid systemic
distribution and offset of drugs or diagnostic agents. This is also pertinent for
many hormones that in the body are secreted in a pulsatile fashion. Many side
effects are associated with having continuous circulating levels of substances
administered. A very pertinent example is female reproductive hormones that
actually have the opposite effect (cause infertility) when continuously present in
the blood. Likewise, continuous and elevated levels of insulin are suspected to
down regulate insulin receptors both in quantity and sensitivity.

[0017] Another benefit of the invention is to achieve higher bioavailabilities
of drugs or diagnostic agents. This effect has been most dramatic for ID
administration of high molecular weight substances, especially proteins, peptides,
and polysaccharides. The direct benefit is that ID administration with enhanced
bioavailability, allows equivalent biological effects while using less active agent.
This results in direct economic benefit to the drug manufacturer and perhaps
consumer, especially for expensive protein therapeutics and diagnostics.
Likewise, higher bioavailability may allow reduced overall dosing and decrease
the patient's side effects associated with higher dosing.

[0018] Another benefit of the invention is the attainment of higher maximum
centralizations of drugs or diagnostic substances. The inventors have found that
substances administered ID are absorbed more rapidly, with bolus administration
resulting in higher initial concentrations. This is most beneficial for substances
whose efficacy is related to maximal concentration. The more rapid onset allows
higher $C_{Max}$ values to be reached with lesser amounts of the substance. Therefore,
the dose can be reduced, providing an economic benefit, as well as a physiological
benefit since lesser amounts of the drug or diagnostic agent has to be cleared by the body.

[0019] Another benefit of the invention is no change in systemic elimination rates or intrinsic clearance mechanisms of drugs or diagnostic agents. All studies to date by the applicants have maintained the same systemic elimination rate for the substances tested as via IV or SC dosing routes. This indicates this dosing route has no change in the biological mechanism for systemic clearance. This is advantageous from a regulatory standpoint, since degradation and clearance pathways need not be reinvestigated prior to filing for FDA approval. This is also beneficial from a pharmacokinetics standpoint, since it allows predictability of dosing regimes. Some substances may be eliminated from the body more rapidly if their clearance mechanism is concentration dependent. Since ID delivery results in higher C_{max}, clearance rate may be altered, although the intrinsic mechanism remains unchanged.

[0020] Another benefit of the invention is no change in pharmacodynamic mechanism or biological response mechanism. As stated above, administered drugs by the methods taught by the applicants still exert their effects by the same biological pathways that are intrinsic to other delivery means. Any pharmacodynamic changes are related only to the difference patterns of appearance, disappearance, and drug or diagnostic agent concentrations present in the biological system.

[0021] Another benefit of the invention is removal of the physical or kinetic barriers invoked when drugs pass through and becomes trapped in cutaneous tissue compartments prior to systemic absorption. Elimination of such barriers leads to an extremely broad applicability to various drug classes. Many drugs administered subcutaneously exert this depot effect - that is, the drug is slowly released from the SC space, in which it is trapped, as the rate determining step prior to systemic absorption, due to affinity for or slow diffusion through the fatty adipose tissue. This depot effect results in a lower C_{max} and longer T_{max}, compared to ID, and can result in high inter-individual variability of absorption.
This effect is also pertinent for comparison to transdermal delivery methods including passive patch technology, with or without permeation enhancers, iontophoretic technology, sonopheresis, or stratum corneum ablation or disruptive methods. Transdermal patch technology relies on drug partitioning through the highly impermeable stratum corneum and epidermal barriers. Few drugs except highly lipophilic compounds can breach this barrier, and those that do, often exhibit extended biological lifetimes due to tissue saturation and entrapment of the drugs and correspondingly slow absorption rate. Active transdermal means, while often faster than passive transfer means, are still restricted to compound classes that can be moved by charge repulsion or other electronic or electrostatic means, or carried passively through the transient pores caused by cavitation of the tissue during application of sound waves. The stratum corneum and epidermis still provide effective means for inhibiting this transport. Stratum corneum removal by thermal or laser ablation, abrasive means or otherwise, still lacks a driving force to facilitate penetration or uptake of drugs. Direct ID administration by mechanical means overcomes the kinetic barrier properties of skin, and is not limited by the pharmaceutical or physicochemical properties of the drug or its formulation excipients.

[0022] Another benefit of the invention is highly controllable dosing regimens. The applicants have determined that ID infusion studies have demonstrated dosing profiles that are highly controllable and predictable due to the rapid onset and predictable offset kinetics of drugs or diagnostic agents delivered by this route. This allows almost absolute control over the desired dosing regimen when ID delivery is coupled with a fluid control means or other control system to regulate metering of the drug or diagnostic agent into the body. This single benefit alone is one of the principal goals of most drug or diagnostic agent delivery methods. Bolus ID substance administration results in kinetics most similar to IV injection and is most desirable for pain relieving compounds, mealtime insulin, rescue drugs, erectile dysfunction compounds, or other drugs that require rapid onset. Also included would be combinations of substances capable of acting alone or synergistically. Extending the ID administration duration via infusion can effectively mimic SC uptake parameters, but with better
predictability. This profile is particularly good for substances such as growth hormones, or analgesics. Longer duration infusion, typically at lower infusion rates can result in continuous low basal levels of drugs that are desired for anticoagulants, basal insulin, and chronic pain therapy. These kinetic profiles can be combined in multiple fashion to exhibit almost any kinetic profile desired. An example would be to pulsatile delivery of fertility hormone (LHRH) for pregnancy induction, which requires intermittent peaks every 90 minutes with total clearance between pulses. Other examples would be rapid peak onset of drugs for migraine relief, followed by lower levels for pain prophylaxis.

[0023] Another benefit of the invention is reduced degradation of drugs and diagnostic agents and/or undesirable immunogenic activity. Other delivery methods may require that a substance reside in the viable epidermis for sometime during transit; whereupon, the substance may experience metabolic activity or elicit an immune response. Metabolic conversion of substances in the epidermis or sequestration by immunoglobulins reduces the amount of drug available for absorption. Furthermore, production in the epidermis of antibodies to some recombinant proteins may be disadvantageous. The ID administration circumvents this problem by placing the drug directly in the dermis, thus bypassing the epidermis entirely.

[0024] These and other benefits of the invention are achieved by directly targeting absorption by the papillary dermis and by controlled delivery of drugs, diagnostic agents, and other substances to the dermal space of skin. The inventors have found that by specifically targeting the intradermal space and controlling the rate and pattern of delivery, the pharmacokinetics exhibited by specific drugs can be unexpectedly improved, and can in many situations be varied with resulting clinical advantage. Such pharmacokinetics cannot be as readily obtained or controlled by other parenteral administration routes, except by IV access.

[0025] The present invention improves the clinical utility of ID delivery of drugs, diagnostic agents, and other substances to humans or animals. The methods employ dermal-access means (for example a small gauge needle,
especially microneedles), to directly target the intradermal space and to deliver substances to the intradermal space as a bolus or by infusion. It has been discovered that the placement of the dermal-access means within the dermis provides for efficacious delivery and pharmacokinetic control of active substances. The dermal-access means is so designed as to prevent leakage of the substance from the skin and improve adsorption within the intradermal space. Delivery devices that place the dermal-access means at an appropriate depth in the intradermal space and control the volume and rate of fluid delivery provide accurate delivery of the substance to the desired location without leakage.

[0026] Disclosed is a method to increase the rate of uptake for parenterally-administered drugs without necessitating IV access. This effect provides a shorter $T_{\text{max}}$. Potential corollary benefits include higher maximum concentrations for a given unit dose ($C_{\text{max}}$), increased absorption rate, higher bioavailability, more rapid onset of pharmacodynamics or biological effects, and reduced drug depot effects.

[0027] It has also been found that by appropriate depth control of the dermal-access means within the intradermal space that the pharmacokinetics of hormone drugs delivered according to the methods of the invention can, if required, produce similar clinical results to that of conventional SC delivery of the drug. For example, the pharmacokinetics of hormone drugs delivered according to the methods of the invention have been found to be vastly different to the pharmacokinetics of conventional SC delivery of same, indicating that ID administration according to the methods of the invention will provide improved clinical results.

[0028] The changes in pharmacokinetic profile for individual compounds between ID administration vs other non-IV parenteral methods will vary according to the chemical properties of the compounds because these properties govern the interaction, distribution, and retention within intramuscular or subcutaneous tissue compartments more so than they do in the dermis. For example, compounds that are relatively large, having a molecular weight of at
least 1000 Daltons as well as larger compounds of at least 2000 Daltons, at least
4000 Daltons, at least 10,000 Daltons and larger and/or hydrophobic compounds
are expected to show the most significant changes compared to traditional
parenteral methods of administration, such as intramuscular, subcutaneous or
subdermal injection. It is expected that small hydrophilic substances, on the
whole, will exhibit similar kinetics for ID delivery compared to other methods.

DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 shows a timecourse of plasma insulin levels of intradermal
versus subcutaneous bolus administration of fast-acting insulin.

[0030] Figure 2 shows a timecourse of blood glucose levels of intradermal
versus subcutaneous bolus administration of fast-acting insulin.

[0031] Figure 3 shows a comparison of bolus ID dosing of fast-acting insulin
versus regular insulin.

[0032] Figure 4 shows the effects of different intradermal injection depths for
bolus dosing of fast-acting insulin on the timecourse of insulin levels.

[0033] Figure 5 shows a comparison of the timecourse of insulin levels for
bolus dosing of long-acting insulin administered subcutaneously or intradermally.

[0034] Figure 6 and 7 show a comparison of the pharmacokinetic availability
and the pharmacodynamic results of granulocyte colony stimulating factor
delivered intradermally with a single needle or three point needle array,
subcutaneously, or intravenously.

[0035] Figures 8, 9 and 10 show a comparison of Low Molecular Weight
Heparin intradermal delivery by bolus, short duration, long duration infusion with
comparison to subcutaneous bolus and infusion.

[0036] Figure 11 shows a timecourse of serum concentration of hGH
administered by bolus administration via single and array microneedles.

DETAILED DESCRIPTION OF THE INVENTION

[0037] The present invention provides a method for therapeutic treatment by
delivery of a drug or other substance to a human or animal subject by directly
targeting the intradermal space, where the drug or substance is administered to the
intradermal space through one or more dermal-access means incorporated within
the device. Substances administered by bolus or infusion according to the
methods of the invention have been found to exhibit pharmacokinetics superior to,
and more clinically desirable than that observed for the same substance
administered by SC injection.

[0038] The dermal-access means used for ID administration according to the
invention is not critical as long as it penetrates the skin of a subject to the desired
targeted depth within the intradermal space without passing through it. In most
cases, the device will penetrate the skin and to a depth of about 0.3-2 mm. The
dermal-access means may comprise conventional injection needles, catheters or
microneedles of all known types, employed singularly or in multiple needle
arrays. The dermal-access means may comprise needleless or needle-free devices
including ballistic injection devices or thermal depth poration devices combined
with a substance driving means. The terms "needle" and "needles" as used herein
are intended to encompass all such needle-like structures. The term microneedles
as used herein are intended to encompass structures smaller than about 30 gauge,
typically about 31-50 gauge when such structures are cylindrical in nature. Non-
cylindrical structures encompass by the term microneedles would therefore be of
comparable diameter and include pyramidal, rectangular, octagonal, wedged, and
other geometrical shapes. Dermal-access means also include ballistic fluid
injection devices, powder-jet delivery devices, piezoelectric, electromotive, and
electromagnetic assisted delivery devices, gas-assisted delivery devices, which
directly penetrate the skin to provide access for delivery, or directly deliver
substances to the targeted location within the dermal space. By varying the
targeted depth of delivery of substances by the dermal-access means,
pharmacokinetic and pharmacodynamic (PK/PD) behavior of the drug or
substance can be tailored to the desired clinical application most appropriate for a
particular patient's condition. The targeted depth of delivery of substances by the
dermal-access means may be controlled manually by the practitioner, or with or
without the assistance of indicator means to indicate when the desired depth is
reached. Preferably however, the device has structural means for controlling skin
penetration to the desired depth within the intradermal space. This is most
typically accomplished by means of a widened area or hub associated with the
shaft of the dermal-access means that may take the form of a backing structure or
platform to which the needles are attached. The length of microneedles as dermal-
access means are easily varied during the fabrication process and are routinely
produced in less than 2 mm length. Microneedles are also a very sharp and of a
very small gauge, to further reduce pain and other sensation during the injection or
infusion. They may be used in the invention as individual single-lumen
microneedles or multiple microneedles may be assembled or fabricated in linear
arrays or two- or three-dimensional arrays as to increase the rate of delivery or the
amount of substance delivered in a given period of time. Microneedles may be
incorporated into a variety of devices such as holders and housings that may also
serve to limit the depth of penetration. The dermal-access means of the invention
may also incorporate reservoirs to contain the substance prior to delivery or
pumps or other means for delivering the drug or other substance under pressure.
Alternatively, the device housing the dermal-access means may be linked
externally to such additional components.

[0039] IV-like pharmacokinetics is accomplished by administering drugs into
the dermal compartment in intimate contact with the capillary microvasculature
and lymphatic microvasculature. In should be understood that the terms
microcapillaries or capillary beds refer to either vascular or lymphatic drainage
pathways within the dermal area.

[0040] While not intending to be bound by any theoretical mechanism of
action, it is believed that the rapid absorption observed upon administration into
the dermis is achieved as a result of the rich plexuses of blood and lymphatic
vessels in the dermis. However, the presence of blood and lymphatic plexuses in
the dermis would not by itself be expected to produce an enhanced absorption of
macromolecules. This is because capillary endothelium is normally of low
permeability or impermeable to macromolecules such as proteins,
 polysaccharides, nucleic acid polymers, substances having polymers attached such
as pegylated proteins and the like. Such macromolecules have a molecular weight
of at least 1000 Daltons or of a higher molecular weight of at least, 2000 Daltons,
at least 4000 Daltons, at least 10,000 Daltons or even higher. Furthermore, a relatively slow lymphatic drainage from the interstitium into the vascular compartment would also not be expected to produce a rapid increase in plasma concentration upon placement of a pharmaceutical substance into the dermis.

[0041] One possible explanation for the unexpected enhanced absorption reported herein is that upon injection of substances, so that they readily reach the papillary dermis, an increase in blood flow and capillary permeability results. For example, it is known that a pinprick insertion to a depth of 3 mm produces an increase in blood flow and this has been postulated to be independent of pain stimulus and due to tissue release of histamine (Arildsson et al., Microvascular Res. 59:122-130, 2000). This is consistent with the observation that an acute inflammatory response elicited in response to skin injury produces a transient increase in blood flow and capillary permeability (see Physiology, Biochemistry, and Molecular Biology of the Skin, Second Edition, L.A. Goldsmith, Ed., Oxford Univ. Press, New York, 1991, p. 1060; Wilhem, Rev. Can. Biol. 30:153-172, 1971). At the same time, the injection into the intradermal layer would be expected to increase interstitial pressure. It is known that increasing interstitial pressure from values beyond the normal range of about −7 to about +2 mmHg distends lymphatic vessels and increases lymph flow (Skobe et al., J. Investig. Dermatol. Symp. Proc. 5:14-19, 2000). Thus, the increased interstitial pressure elicited by injection into the intradermal layer is believed to elicit increased lymph flow and increased absorption of substances injected into the dermis.

[0042] By “improved pharmacokinetics” it is meant that an enhancement of pharmacokinetic profile is achieved as measured, for example, by standard pharmacokinetic parameters such as time to maximal plasma concentration (T_{\text{max}}), the magnitude of maximal plasma concentration (C_{\text{max}}) or the time to elicit a minimally detectable blood or plasma concentration (T_{\text{lag}}) or absorption rate from the administration site. By enhanced absorption profile, it is meant that absorption is improved or greater as measured by such pharmacokinetic parameters. The measurement of pharmacokinetic parameters and determination of minimally effective concentrations are routinely performed in the art. Values obtained are
deemed to be enhanced by comparison with a standard route of administration such as, for example, subcutaneous administration or intramuscular administration. In such comparisons, it is preferable, although not necessarily essential, that administration into the intradermal layer and administration into the reference site such as subcutaneous administration involve the same dose levels, i.e. the same amount and concentration of drug as well as the same carrier vehicle and the same rate of administration in terms of amount and volume per unit time. Thus, for example, administration of a given pharmaceutical substance into the dermis at a concentration such as 100 μg/ml and rate of 100 μL per minute over a period of 5 minutes would, preferably, be compared to administration of the same pharmaceutical substance into the subcutaneous space at the same concentration of 100 μg/ml and rate of 100 μL per minute over a period of 5 minutes.

[0043] The enhanced absorption profile is believed to be particularly evident for substances, which are not well absorbed when injected subcutaneously such as, for example, macromolecules and/or hydrophobic substances. Macromolecules are, in general, not well absorbed subcutaneously and this may be due, not only to their size relative to the capillary pore size, it may also be due to their slow diffusion through the interstitium because of their size. It is understood that macromolecules can possess discrete domains having a hydrophobic and/or hydrophilic nature. In contrast, small molecules that are hydrophilic are generally well absorbed when administered subcutaneously and it is possible that no enhanced absorption profile would be seen upon injection into the dermis compared to absorption following subcutaneous administration. Reference to hydrophobic substances herein is intended to mean low molecular weight substances, for example substances with molecular weights less than 1000 Daltons, which have a water solubility which is low to substantially insoluble.

[0044] The above-mentioned PK and PD benefits are best realized by accurate direct targeting of the dermal capillary beds. This is accomplished, for example, by using microneedle systems of less than about 250 micron outer diameter, and less than 2 mm exposed length. Such systems can be constructed using known methods of various materials including steel, glass, silicon, ceramic, other metals,
plastic, polymers, sugars, biological and or biodegradable materials, and/or combinations thereof.

[0045] It has been found that certain features of the intradermal administration methods provide clinically useful PK/PD and dose accuracy. For example, it has been found that placement of the needle outlet within the skin significantly affects PK/PD parameters. The outlet of a conventional or standard gauge needle with a bevel has a relatively large exposed height (the vertical rise of the outlet). Although the needle tip may be placed at the desired depth within the intradermal space, the large exposed height of the needle outlet causes the delivered substance to be deposited at a much shallower depth nearer to the skin surface. As a result, the substance tends to effuse out of the skin due to backpressure exerted by the skin itself and to pressure built up from accumulating fluid from the injection or infusion. That is, at a greater penetration depth a needle outlet with a greater exposed height will still seal efficiently where as an outlet with the same exposed height will not seal efficiently when placed in a shallower depth within the intradermal space. Typically, the exposed height of the needle outlet will be from 0 to about 1 mm. A needle outlet with an exposed height of 0 mm has no bevel and is at the tip of the needle. In this case, the depth of the outlet is the same as the depth of penetration of the needle. A needle outlet that is either formed by a bevel or by an opening through the side of the needle has a measurable exposed height. It is understood that a single needle may have more than one opening or outlets suitable for delivery of substances to the dermal space.

[0046] It has also been found that by controlling the pressure of injection or infusion may avoid the high backpressure exerted during ID administration. By placing a pressure directly on the liquid interface a more constant delivery rate can be achieved, which may optimize absorption and obtain the improved pharmacokinetics. Delivery rate and volume can also be controlled to prevent the formation of wheals at the site of delivery and to prevent backpressure from pushing the dermal-access means out of the skin. The appropriate delivery rates and volumes to obtain these effects for a selected substance may be determined experimentally using only ordinary skill. Increased spacing between multiple
needles allows broader fluid distribution and increased rates of delivery or larger fluid volumes. In addition, it has been found that ID infusion or injection often produces higher initial plasma levels of drug than conventional SC administration, particularly for drugs that are susceptible to in vivo degradation or clearance or for compounds that have an affinity to the SC adipose tissue or for macromolecules that diffuse slowly through the SC matrix. This may, in many cases, allow for smaller doses of the substance to be administered via the ID route.

[0047] The administration methods useful for carrying out the invention include both bolus and infusion delivery of drugs and other substances to humans or animals subjects. Using the methods of the present invention, pharmaceutical compounds may be administered as a bolus, or by infusion. As used herein, the term “bolus” is intended to mean an amount that is delivered within a time period of less than ten (10) minutes. “Infusion” is intended to mean the delivery of a substance over a time period greater than ten (10) minutes. It is understood that bolus administration or delivery can be carried out with rate controlling means, for example a pump, or have no specific rate controlling means, for example user self-injection. Such rate controlling means include programmed delivery of substances, for example, in a pulsatile manner, by way of example, substances administered via a bolus followed by a short or long term infusion. A bolus dose is a single dose delivered in a single volume unit over a relatively brief period of time, typically less than about 10 minutes. Infusion administration comprises administering a fluid at a selected rate that may be constant or variable, over a relatively more extended time period, typically greater than about 10 minutes. To deliver a substance the dermal-access means is placed adjacent to the skin of a subject providing directly targeted access within the intradermal space and the substance or substances are delivered or administered into the intradermal space where they can act locally or be absorbed into the bloodstream or lymphatic circulation and be distributed systemically. The dermal-access means may be connected to a reservoir containing the substance or substances to be delivered. The form of the substance or substances to be delivered or administered include solutions, emulsions, suspensions, gels, particulates such as micro- and nanoparticles either suspended or dispersed, as well as in-situ forming vehicles of
the same. Delivery from the reservoir into the intradermal space may occur either passively, without application of the external pressure or other driving means to the substance or substances to be delivered, and/or actively, with the application of pressure or other driving means. Examples of preferred pressure generating means include pumps, syringes, elastomer membranes, gas pressure, piezoelectric or electromotive or electromagnetic pumping, or Belleville springs or washers or combinations thereof. If desired, the rate of delivery of the substance may be variably controlled by the pressure-generating means. As a result, the substance enters the intradermal space and is absorbed in an amount and at a rate sufficient to produce a clinically efficacious result.

[0048] As used herein, the term "clinically efficacious result" is meant a clinically useful biological response including both diagnostically and therapeutically useful responses, resulting from administration of a substance or substances. For example, diagnostic testing or prevention or treatment of a disease or condition is a clinically efficacious result. Such clinically efficacious results include diagnostic results such as the measurement of glomerular filtration pressure following injection of inulin, the diagnosis of adrenocortical function in children following injection of ACTH, the causing of the gallbladder to contract and evacuate bile upon injection of cholecystokinin and the like as well as therapeutic results, such as clinically adequate control of blood sugar levels upon injection of insulin, clinically adequate management of hormone deficiency following hormone injection such as parathyroid hormone or growth hormone, clinically adequate treatment of toxicity upon injection of an antitoxin and the like.

[0049] Substances that can be delivered intradermally in accordance with the present invention are intended to include pharmaceutically or biologically active substances including diagnostic agents, drugs, and other substances which provide therapeutic or health benefits such as for example nutraceuticals. Diagnostic substances useful with the present invention include macromolecular substances such as, for example, insulin, ACTH (e.g. corticotropin injection), luteinizing hormone-releasing hormone (e.g., Gonadorelin Hydrochloride), growth hormone-
releasing hormone (e.g. Sermorelin Acetate), cholecystokinin (Sinclade),
parathyroid hormone and fragments thereof (e.g. Teriparatide Acetate), thyroid
releasing hormone and analogs thereof (e.g. protirelin), secretin and the like.

[0050] Therapeutic substances which can be used with the present invention
include Alpha-1 anti-trypsin, Anti-Angiogenesis agents, Antisense, butorphanol,
Calcitonin and analogs, Ceredase, COX-II inhibitors, dermatological agents,
dihydroergotamine, Dopamine agonists and antagonists, Enkephalins and other
opioid peptides, Epidermal growth factors, Erythropoietin and analogs, Follicle
stimulating hormone, G-CSF, Glucagon, GM-CSF, granisetron, Growth hormone
and analogs (including growth hormone releasing hormone), Growth hormone
antagonists, Hirudin and Hirudin analogs such as Hirulog, IgE suppressors,
Insulin, insulinotropin and analogs, Insulin-like growth factors, Interferons,
Interleukins, Luteinizing hormone, Luteinizing hormone releasing hormone and
analogs, Heparins, Low molecular weight heparins and other natural, modified, or
synthetic glycoaminoglycans, M-CSF, metoclopramide, Midazolam, Monoclonal
antibodies, Peglyated antibodies, PEGylated proteins or any proteins modified
with hydrophilic or hydrophobic polymers or additional functional groups, Fusion
proteins, Single chain antibody fragments or the same with any combination of
attached proteins, macromolecules, or additional functional groups thereof,
Narcotic analgesics, nicotine, Non-steroid anti-inflammatory agents,
Oligosaccharides, ondansetron, Parathyroid hormone and analogs, Parathroid
hormone antagonists, Prostaglandin antagonists, Prostaglandins, Recombinant
soluble receptors, scopolamine, Serotonin agonists and antagonists, Sildenafil,
Terbutaline, Thrombolytics, Tissue plasminogen activators, TNF -, and TNF -
antagonist, the vaccines, with or without carriers/adjuvants, including
prophylactics and therapeutic antigens (including but not limited to subunit
protein, peptide and polysaccharide, polysaccharide conjugates, toxoids, genetic
based vaccines, live attenuated, reassortant, inactivated, whole cells, viral and
bacterial vectors) in connection with, addiction, arthritis, cholera, cocaine
addiction, diphtheria, tetanus, Hib, Lyme disease, meningococcus, measles,
mumps, rubella, varicella, yellow fever, Respiratory syncytial virus, tick borne
Japanese encephalitis, pneumococcus, streptococcus, typhoid, influenza, hepatitis,
including hepatitis A, B, C and E, otitis media, rabies, polio, HIV, parainfluenza, rotavirus, Epstein Barr Virus, CMV, chlamydia, non-typeable haemophilus, moraxella catarrhalis, human papilloma virus, tuberculosis including BCG, gonorrhoea, asthma, atherosclerosis malaria, E-coli, Alzheimer’s Disease, H. Pylori, salmonella, diabetes, cancer, herpes simplex, human papilloma and the like other substances including all of the major therapeutics such as agents for the common cold, Anti-addiction, anti-allergy, anti-emetics, anti-obesity, antiosteoporetic, anti-infectives, analgesics, anesthetics, anorexics, antiarthritis, antiasthmatic agents, anticonvulsants, anti-depressants, antidiabetic agents, antihistamines, anti-inflammatories agents, antimigraine preparations, antimitosis sickness preparations, antiaesants, antineoplastics, antiparkinsonism drugs, antipruritics, antipsychotics, antipyretics, anticholinergics, benzodiazepine antagonists, vasodilators, including general, coronary, peripheral and cerebral, bone stimulating agents, central nervous system stimulants, hormones, hypnotics, immunosuppressives, muscle relaxants, parasympatholytics, parasympathomimetics, prostaglandins, proteins, peptides, polypeptides and other macromolecules, psychostimulants, sedatives, and sexual hypofunction and tranquilizers.

[0051] Pharmacokinetic analysis of insulin infusion data was carried out as follows. Stepwise nonlinear least-squares regression was used to analyze the insulin concentration-time data from each individual animal. Initially, an empirical biexponential equation was fit to the insulin concentration-time data for the negative control condition. This analysis assumed first-order release of residual insulin, and recovered parameters for the first-order rate constant for release, the residual insulin concentration at the release site, a lag time for release, and a first-order rate constant for elimination of insulin from the systemic circulation. The parameters recovered in this phase of the analysis are of no intrinsic importance, but merely account for the fraction of circulating insulin derived from endogenous sources.

[0052] The second step of the analysis involved fitting an explicit compartmental model to the insulin concentration-time data during and after
subcutaneous or intradermal infusion. Infusion of insulin proceeded from \( t = 0 \) to \( t = 240 \) min; after a lag time \( (t_{\text{lag,2}}) \), absorption from the infusion site was mediated by a first-order process governed by the absorption rate constant \( k_a \). Insulin absorbed into the systemic circulation distributed into an apparent volume \( V \) contaminated by an unknown fractional bioavailability \( F \), and was eliminated according to a first-order rate constant \( K \). The fitting routine recovered estimates of \( t_{\text{lag,2}}, k_a, V/F, \) and \( K \); parameters associated with the disposition of endogenous insulin \( (C_R, t_{\text{lag,1}}, k_R) \), which were recovered in the first step of the analysis, were treated as constants.

Parameter estimates are reported as mean ± SD. The significance of differences in specific parameters between the two different modes of insulin administration (subcutaneous versus intradermal infusion) was assessed with the paired Student’s t-test.

Pharmacodynamic analysis of insulin infusion data was calculated as follows. Plasma concentrations of glucose were used as a surrogate for the pharmacologic effect of insulin. The change in response variable \( R \) (plasma glucose concentration) with respect to time \( t \) was modeled as

\[
\frac{dR}{dt} = k_{in} - E \cdot k_{out}
\]

where \( k_{in} \) is the zero-order infusion of glucose, \( k_{out} \) is the first-order rate constant mediating glucose elimination, and \( E \) is the effect of insulin according to the sigmoidal Hill relationship

\[
E = \frac{E_{max} \cdot C^\gamma}{EC_{50}^\gamma + C^\gamma}
\]

in which \( E_{max} \) is the maximal stimulation of \( k_{out} \) by insulin, \( EC_{50} \) is the insulin concentration at which stimulation of \( k_{out} \) is half maximal, \( C \) is the concentration of insulin, and \( \gamma \) is the Hill coefficient of the relationship. Initial
modeling efforts utilized the plasma concentration of insulin as the mediator of pharmacologic response. However, this approach did not capture the delay in response of plasma glucose to increasing concentrations of plasma insulin. Therefore, an effect-compartment modeling approach was finally adopted in which the effect of insulin was mediated from a hypothetical effect compartment peripheral to the systemic pharmacokinetic compartment.

[0057] The pharmacodynamic analysis was conducted in two steps. In the first step of the analysis, initial estimates of the pharmacokinetic parameters associated with the disposition of glucose ($k_{\text{out}}$ and the volume of distribution of glucose, $V_{\text{glucose}}$) were determined from the glucose concentration-time data in the negative control condition. The full integrated pharmacokinetic-pharmacodynamic model then was fit simultaneously to the glucose concentration-time data from the negative control condition and each insulin delivery condition for each animal (i.e., two sets of pharmacodynamic parameters were obtained for each animal: one from the simultaneous analysis of the subcutaneous insulin infusion/negative control data, and one from the simultaneous analysis of the intradermal insulin infusion/negative control data). In all pharmacodynamic analyses, the parameters governing insulin disposition obtained during pharmacokinetic analysis of insulin concentration-time data from each animal were held constant.

[0058] All other pharmacokinetic analyses were calculated using non-compartmental methods using similar software programs and techniques known in the art.

[0059] Having described the invention in general, the following specific but not limiting examples and reference to the accompanying Figures set forth various examples for practicing the dermal accessing, direct targeting drug administration method and examples of dermally administered drug substances providing improved PK and PD effects.

[0060] A representative example of dermal-access microdevice comprising a single needle was prepared from 34 gauge steel stock (MicroGroup, Inc.,
Medway, MA) and a single 28° bevel was ground using an 800 grit carborundum grinding wheel. Needles were cleaned by sequential sonication in acetone and distilled water, and flow-checked with distilled water. Microneedles were secured into small gauge catheter tubing (Maersk Medical) using UV-cured epoxy resin. Needle length was set using a mechanical indexing plate, with the hub of the catheter tubing acting as a depth-limiting control and was confirmed by optical microscopy. For experiments using single needles of various lengths, the exposed needle lengths were adjusted to 0.5 or 1 mm using an indexing plate. Connection to the fluid metering device, either pump or syringe, was via an integral Luer adapter at the catheter inlet. During injection, needles were inserted perpendicular to the skin surface, and were either held in place by gentle hand pressure for bolus delivery or held upright by medical adhesive tape for longer infusions. Devices were checked for function and fluid flow both immediately prior to and post injection. This Luer Lok single needle catheter design is hereafter designated SS1_34.

Yet another dermal-access array microdevices was prepared consisting of 1" diameter disks machined from acrylic polymer, with a low volume fluid path branching to each individual needle from a central inlet. Fluid input was via a low volume catheter line connected to a Hamilton microsyringe, and delivery rate was controlled via a syringe pump. Needles were arranged in the disk with a circular pattern of 15 mm diameter. Three-needle and six-needle arrays were constructed, with 12 and 7 mm needle-to-needle spacing, respectively. All array designs used single-bevel of 28°, 34 G stainless steel microneedles of 1 mm length. The 3-needle 12mm spacing catheter-design is hereafter designated SS3_34, 6-needle 7mm spacing catheter-design is hereafter designated SS6_34.

Yet another dermal-access array microdevices was prepared consisting of 11mm diameter disks machined from acrylic polymer, with a low volume fluid path branching to each individual needle from a central inlet. Fluid input was via a low volume catheter line connected to a Hamilton microsyringe, and delivery rate was controlled via a syringe pump. Needles were arranged in the disk with a circular pattern of about 5 mm diameter. Three-needle arrays of about 4 mm
spacing connected to a catheter as described above. These designs are hereafter designated SS3S_34_1, SS3S_34_2, and SS3S_34_3 for 1mm, 2mm, and 3mm needle lengths respectively.

[0063] Yet another dermal-access ID infusion device was constructed using a stainless steel 30 gauge needle bent at near the tip at a 90-degree angle such that the available length for skin penetration was 1-2 mm. The needle outlet (the tip of the needle) was at a depth of 1.7-2.0 mm in the skin when the needle was inserted and the total exposed height of the needle outlet was 1.0-1.2 mm. This design is hereafter designated SSB1_30.

[0064] EXAMPLE I
[0065] Slow-infusion ID insulin delivery was demonstrated in swine using a hollow, silicon-based single-lumen microneedle (2 mm total length and 200 X 100 μm OD, corresponding to about 33 gauge) with an outlet 1.0 μm from the tip (100 μm exposed height), was fabricated using processes known in the art (US Patent No. 5,928,207) and mated to a microbore catheter (Disetronic). The distal end of the microneedle was placed into the plastic catheter and cemented in place with epoxy resin to form a depth-limiting hub. The needle outlet was positioned approximately 1 mm beyond the epoxy hub, thus limiting penetration of the needle outlet into the skin to approximately 1 mm, which corresponds to the depth of the intradermal space in swine. The catheter was attached to a MiniMed 507 insulin pump for control of fluid delivery. The patency of the fluid flow path was confirmed by visual observation, and no obstructions were observed at pressures generated by a standard 1-cc syringe. The catheter was connected to an external insulin infusion pump (MiniMed 507) via the integral Luer connection at the catheter outlet. The pump was filled with Humalog™ (Lispro) insulin (Eli Lilly, Indianapolis, IN) and the catheter and microneedle were primed with insulin according to the manufacturer’s instructions. Sandostatin® (Sandoz, East Hanover, NJ) solution was administered via IV infusion to anesthetized swine to suppress basal pancreatic function and insulin secretion. After a suitable induction period and baseline sampling, the primed microneedle was inserted perpendicular to the skin surface in the flank of the animal up to the hub stop.
Insulin infusion at a rate of 2 U/hr was used and maintained for 4 hr. Blood samples were periodically withdrawn and analyzed for serum insulin concentration and blood glucose values. Baseline insulin levels before infusion were at the background detection level of the assay. After initiation of the infusion, serum insulin levels showed an increase that was commensurate with the programmed infusion rates. Blood glucose levels also showed a corresponding drop relative to negative controls (NC) without insulin infusion and this drop was improved relative to conventional SC infusion. In this experiment, the microneedle was demonstrated to adequately breach the skin barrier and deliver a drug in vivo at pharmaceutically relevant rates. The ID infusion of insulin was demonstrated to be a pharmacokinetically acceptable administration route, and the pharmacodynamic response of blood glucose reduction was also demonstrated. Calculated PK parameters for ID infusion indicate that insulin is absorbed much faster than via than SC administration. Absorption from the ID space begins almost immediately: the lag time prior to absorption \(T_{lag}\) was 0.88 vs. 13.6 min for ID and SC respectively. Also the rate of uptake from the administration site is increased by approximately 3-fold, \(k_u = 0.0666\) vs. \(0.0225\) min\(^{-1}\) for ID and SC respectively. The bioavailability of insulin delivered by ID administration is increased approximately 1.3 fold greater than SC administration.

[0066] EXAMPLE II
[0067] Bolus delivery of Lilly Lispro fast acting insulin was performed using ID and SC bolus administration. The ID injection microdevice was dermal access array design SS3S_34_1. 10 international insulin units (U) corresponding to 100 uL volume respectively, were administered to diabetic Yucatan Mini swine. Test animals had been previously been rendered diabetic by chemical ablation of pancreatic islet cells, and were no longer able to secrete insulin. Test animals received their insulin injection either via the microneedle array or via a standard 30 G X \(\frac{1}{2}\) in. needle inserted laterally into the SC tissue space. Circulating serum insulin levels were detected using a commercial chemiluminescent assay kit (Immulite, Los Angeles, CA) and blood glucose values were determined using blood glucose strips. ID injections were accomplished via hand pressure using an analytical microsyringe and were administered over approximately 60 sec. By
comparison, SC dosing required only 2-3 sec. Referring to Figure 1, it is shown that serum insulin levels after bolus administration demonstrate more rapid uptake and distribution of the injected insulin when administered via the ID route. The time to maximum concentration ($T_{\text{max}}$) is shorter and the maximum concentration obtained ($C_{\text{max}}$) is higher for ID vs. SC administration. In addition, Figure 2 also demonstrates the pharmacodynamic biological response to the administered insulin, as measured by the decrease in blood glucose (BG), showed faster and greater changes in BG since more insulin was available early after ID administration.

[0068] EXAMPLE III

[0069] Lilly Lispro is regarded as fact acting insulin, and has a slightly altered protein structure relative to native human insulin. Hoechst regular insulin maintains the native human insulin protein structure that is chemically similar, but has slower uptake than Lispro when administered by the traditional SC route. Both insulin types were administered in bolus via the ID route to determine if any differences in uptake would be discernable by this route. 5U of either insulin type were administered to the ID space using dermal access microdevice design SS3S_34_1. The insulin concentration verses time data shown in Figure 3. When administered by the ID route the PK profiles for regular and fast-acting insulin were essentially identical, and both insulin types exhibited faster uptake than Lispro given by the traditional SC route. This is evidence that the uptake mechanism for ID administration is minimally affected by minor biochemical changes in the administered substance, and that ID delivery provides an advantageous PK uptake profile for regular insulin that is superior to SC administered fast-acting insulin.

[0070] EXAMPLE IV

[0071] Bolus delivery of Lilly Lispro fast-acting insulin via microneedle arrays having needles of various lengths was conducted to demonstrate that the precise deposition of drug into the dermal space is necessary to obtain the PK advantages and distinctions relative to SC. Thus, 5U of Lilly Lispro fast-acting insulin was administered using dermal access designs SS3S_34_1, SS3S_34_2,
SS3S_34_3. The average total dermal thickness in Yucatan Mini swine ranges from 1.5-2.5 mm. Therefore insulin deposition is expected to be into the dermis, approximately at the dermal/SC interface, and below the dermis and within the SC for 1mm, 2mm, and 3mm length needles respectively. Bolus insulin administration was as described in EXAMPLE II. Average insulin concentrations verses time is shown in Figure 4. The data clearly shows as microneedle length is increased, the resulting PK profile begins to more closely resemble SC administration. This data demonstrates the benefits of directly targeting the dermal space, such benefits include rapid uptake and distribution, and high initial concentrations. Since the data are averages of multiple examples, they do not show the increased inter-individual variability in PK profiles from longer 2 and 3mm microneedles. This data demonstrates that since skin thickness may vary both between individuals and even within a single individual, shorter needle lengths that accurately target the dermal space are more reproducible in their PK profile since they are depositing the drug more consistently in the same tissue compartment. This data demonstrates longer microneedles that deposit or administer substances deeper into the dermal space, or partially or wholly into the SC space, mitigate or eliminate the PK advantages in comparison to shallow, directly targeted administrations to the highly vascularized dermal region.

[0072] EXAMPLE V

[0073] Bolus delivery of Lantus long-acting insulin was delivered via the ID route. Lantus is an insulin solution that forms microprecipitates at the administration site upon injection. These microparticulates undergo slow dissolution within the body to provide (according to the manufacturer’s literature) a more stable low level of circulating insulin than other current long-acting insulin such as crystalline zinc precipitates (e.g. Lente, NPH). Lantus insulin (10 U dose, 100 uL) was administered to diabetic Yucatan Mini pigs using the dermal access design SS3S_34_1 and by the standard SC method as previously described. Referring to Figure 5, when administered via the ID route, similar PK profiles were obtained relative to SC. Minor distinctions include a slightly higher “burst” immediately after the ID insulin delivery. This demonstrates that the uptake of even very high molecular weight compounds or small particles is achievable via
ID administration. More importantly this supports the fact that the biological clearance mechanism in the body is not appreciably changed by the administration route, nor is the way in which that the drug substance is utilized. This is extremely important for drugs compounds that have a long circulating half-life (examples would be large soluble receptor compounds or antibodies, or chemically modified species such as PEGylated drugs).

[0074] EXAMPLE VI

[0075] Bolus ID delivery of human granulocyte colony stimulating factor (GCSF) (Neupogen®) was administered via dermal access microdevice designs SS3_34 (array) or SS1_34 (single needle) to Yucatan minipigs. Delivery rate was controlled via a Harvard syringe pump and was administered over a 1-2.5 min period. Figure 6 shows the PK availability of GCSF in blood plasma as detected by an ELISA immunoassay specific for GCSF. Administration via IV and SC delivery was performed as controls. Referring to Figure 6 bolus ID delivery of GCSF shows the more rapid uptake associated with ID delivery. C_{max} is achieved at approximately 30-90 minutes for ID administration vs. 120 min for SC administration. Also the bioavailability is dramatically increased by an approximate factor of 2 as evidenced by the much higher area under the curve (AUC). Circulating levels of GCSF are detectable for an extended period, indicting that ID delivery does not alter the intrinsic biological clearance mechanism or rate for the drug. These data also show that device design has minimal effect on the rapid uptake of drug from the ID space. The data referred to in Figure 7 also shows the degree and time course of white blood cell expansion as a result of GCSF administration with respect to a negative control (no GCSF administered). White blood cell (WBC) counts were determined by standard cytometric clinical veterinary methods. ID delivery exhibits the same clinically significant biological outcomes. Although all delivery means give approximately equal PD outcomes, this data suggests ID delivery could enable use of half the SC administered dose to achieve essentially the same physiological result due to approximately 2-fold bioavailability increase.

[0076] EXAMPLE VII
An ID administration experiment was conducted using a peptide drug entity: human parathyroid hormone 1-34 (PTH). PTH was infused for a 4h period, followed by a 2h clearance. Control SC infusion was through a standard needle inserted into the SC space lateral to the skin using a “pinch-up” technique. ID infusion was through dermal access microdevice design SSB1_30 (a stainless steel 30-gauge needle bent at the tip at a 90° angle such that the available length for skin penetration was 1-2 mm). The needle outlet (the tip of the needle) was at a depth of 1.7-2.0 mm in the skin when the needle was inserted. A 0.64 mg/mL PTH solution was infused at a rate of 75 µL/hr. Flow rate was controlled via a Harvard syringe pump. The weight normalized delivery profiles for ID administration have a larger area under the curve (AUC) indicating higher bioavailability, higher peak values at earlier sampling timepoints (e.g. 15 and 30 min) indicating more rapid onset from ID delivery, and rapid decrease following termination of infusion (also indicative of rapid uptake without a depot effect compared to SC administration).

[0077] EXAMPLE VIII

[0078] Referring to Figure 8, representative weight normalized plasma profiles following bolus delivery of Fragmin®, (Pharmacia Corporation), Low Molecular Weight Heparin (LMWH) mixture comprised of sulfated glycosaminoglycans ranging in molecular weight from about 1000 to 9000 Daltons, in Yucatan mini-pigs via various dermal access microdevice configurations are presented. In each case the ID delivered dose was 2500 IU (international units) of Fragmin® (100 ul of a 25000 IU/mL formulation). Standard SC delivery was performed via a standard needle inserted laterally into the SC tissue space via a pinch-up technique. Dermal access microdevice designs SS1_34 of 0.5 or 1.0mm needle length connected to catheter tubing were used for dosing. During use the fully exposed length of microneedle was inserted perpendicularly to the skin surface up to the depth-limiter and held in place by mechanical means for the duration of drug instillation. The microneedle bolus injection was via hand pressure from a glass microsyringe over a 1-2.5 min period. The calculated pharmacokinetic results of Table 1 show the increased C_max and decreased T_max resulting from microdevice delivery. The profiles
Table 1. Calculated LMWH PK Data

<table>
<thead>
<tr>
<th>Condition:</th>
<th>SC</th>
<th>1.0 mm microneedle</th>
<th>0.5 mm microneedle</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>$t_{\text{max}}$ (h)</td>
<td>3.0</td>
<td>3.6</td>
<td>1.0</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (IU/mL)</td>
<td>0.6</td>
<td>0.3</td>
<td>1.1</td>
</tr>
</tbody>
</table>

obtained from both microneedle devices were essentially equivalent indicating that the delivery profile is essentially independent of device configuration providing the device appropriately accesses and delivers the drug substance within the targeted dermal tissue compartment. Equivalent changes in pharmacokinetic uptake can be generated using the other dermal access microdevice systems including arrays composed of 3 and 6 microneedles with the same dimensions and seating depths indicated above.

[0079] EXAMPLE IX

[0080] Referring to Figure 9 which shows representative weight normalized plasma profiles of short infusion delivery of Fragmin® LMWH in Yucatan mini-pigs. A total of 2500 IU in a 200 uL volume (12500 IU/mL concentration) of LMWH was infused over durations ranging from 0.5-2.0 h. The volumetric infusion rate ranged between 100-400 uL/h. The dermal access array microdevice was of design SS3_34 connected to a syringe pump for control of fluid delivery. Each microneedle in the array had a 1 mm extended length for insertion. ID bolus injection of an equivalent dose (100 uL of 25000 IU/ml) LMWH over a <2 min period via a similar microneedle array and standard SC bolus administration are shown for comparison. The resulting plasma profiles demonstrate the highly controllable drug delivery profiles obtainable with a microdevice intradermal system. This data demonstrates the infusion control means allows for modulation of the pharmacokinetics via the infusion rate. As volumetric infusion rates decrease, $C_{\text{max}}$ and $T_{\text{max}}$ decrease and increase, respectively. Within experimental error $T_{\text{max}}$ for Fragmin® was routinely obtained at the cessation of the infusion period. This short infusion administration result demonstrates the ability to
deliver greater than normal total fluid volumes than standard ID administrations (Mantoux technique is limited to about 100 to 150uL/dose).

[0081] EXAMPLE X

[0082] Referring to Figure 10, which shows representative weight normalized plasma profiles following slow infusion delivery of Fragmin® LMWH in Yucatan mini-pigs. A total of 2000 IU in an 80 uL volume (25000 IU/mL concentration) of LMWH was infused over a 5 hour period. The volumetric infusion rate was 16 uL/h. The infusion means was a commercial insulin pump connected to either an ID microdevice of design SS1_34, or a commercial insulin infusion catheter. The resulting plasma profiles again indicate the more rapid onset of LMWH infused via microdevices. After removal of the catheter set at 5 hours, the ID delivery exhibited a lack of depot effect, as evidenced by the immediate decline of detectable plasma activity. In contrast, the plasma levels of SC infused LMWH did not peak until 7h, fully 2h after infusion cessation. Neither infusion method reaches steady state over the experimental duration, but this was previously predicted via PK modeling. This example readily demonstrates that the PK advantages of controlled ID delivery are available at low infusion rates, and the degree of control, which can be achieved in dosing profiles. This particular profile would be optimal for drugs such as LMWH, insulin, and other substances that require low continuous circulating basal levels without high peak concentrations.

[0083] EXAMPLE XI

[0084] Referring to Table 2 which shows weight normalized serum levels of hGH after bolus delivery of Genotropin® (Pharmacia Corporation), a recombinant human growth hormone with a molecular weight of about 22,600 Daltons, via intradermal microdevices and standard subcutaneous injection methods of 3.6 IU of Genotropin®. Injection volume was 100 uL and the drug concentration was 36 IU/mL. Dermal access array microdevices were SS1_34 and SS3_34 designs with 1mm exposed needle length. The rate of microdevice injection for both single and three-needle arrays was controlled at 45 uL/min using a syringe pump, for a nominal bolus infusion duration of 2.22 minutes. SC delivery was via a 27 G
insulin catheter, at a 1.0 mL/min flow rate, for a nominal 10 sec injection. The resultant pharmacokinetic distinctions are clearly evident, with ID delivery resulting in drastically decreased $T_{\text{max}}$ and increased $C_{\text{max}}$. Biological half-life, and bioavailability are statistically equivalent for both ID and SC routes. Administrations by either single needle or array intradermal dermal access microdevice configurations produce equivalent pharmacokinetic performance.

Table 2: Calculated PK parameters for hGH administration

<table>
<thead>
<tr>
<th>PK parameters</th>
<th>SC</th>
<th>ID single needle</th>
<th>ID 6-needle array</th>
</tr>
</thead>
<tbody>
<tr>
<td>$Dose$ (IU/kg)</td>
<td>0.16±0.01</td>
<td>0.16±0.01</td>
<td>0.16±0.02</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (mIU/L)</td>
<td>158.5±31.0</td>
<td>612.6±187.1</td>
<td>582.1±391.0</td>
</tr>
<tr>
<td>$t_{\text{max}}$ (h)</td>
<td>2.75±0.46</td>
<td>0.47±0.25</td>
<td>0.63±0.23</td>
</tr>
<tr>
<td>$t_{1/2e}$ (h)</td>
<td>1.19±0.49</td>
<td>2.02±0.48</td>
<td>1.71±0.43</td>
</tr>
<tr>
<td>$AUC_{\text{INF(pred)}}$ (mIU x h/L)</td>
<td>920.2±251.7</td>
<td>850.0±170.0</td>
<td>847.4±332.3</td>
</tr>
<tr>
<td>$F$ (%)</td>
<td>114.6</td>
<td>104.0</td>
<td>101.7</td>
</tr>
</tbody>
</table>

[0085] EXAMPLE XII

[0086] Referring to the data in Table 3, bolus delivery of Almotriptan (Almirall-Prodesfarma), a low molecular weight, highly water soluble antimigraine compound, via intradermal microdevices and standard subcutaneous methods demonstrated statistically equivalent PK profiles. The table below shows calculated PK parameters determined from measured serum levels after injection of 3.0 mg of almotriptan. Injection volume for both SC and ID was 100 µL and the drug concentration was 30 mg/mL. Microdevices designs SS1_34 and SS6_34 were used and administration was over about 2-2.5 minutes. Almotriptan is a small hydrophilic compound that shows no apparent depot from SC injection. Therefore, differences in the pharmacokinetic uptake between ID and SC administration were not observed. This drug substance can readily partition through the tissue space for rapid absorption via either route. However, ID
administration may still be advantageous for reduced patient perception and ready and rapid access to an appropriate administration site.

Table 3: Mean (± standard deviation) almotriptan PK parameters following SC and ID administration

<table>
<thead>
<tr>
<th>Parameters</th>
<th>SC</th>
<th>ID (single)</th>
<th>ID (array)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC_{0-∞} (ng h/mL)</td>
<td>55.9 (6.04)</td>
<td>53.3 (15.7)</td>
<td>54.6 (14.0)</td>
</tr>
<tr>
<td>Clearance (L/hr)</td>
<td>55.1 (5.87)</td>
<td>60.1 (15.3)</td>
<td>58.7 (12.7)</td>
</tr>
<tr>
<td>C_{max} (ng/mL)</td>
<td>61.0 (19.4)</td>
<td>63.6 (26.1)</td>
<td>77.2 (54.2)</td>
</tr>
<tr>
<td>T_{max} (h)</td>
<td>0.13 (0.05)</td>
<td>0.14 (0.08)</td>
<td>0.16 (0.08)</td>
</tr>
<tr>
<td>t_{1/2} (h)</td>
<td>1.95 (0.23)</td>
<td>2.03 (0.46)</td>
<td>2.39 (0.64)</td>
</tr>
</tbody>
</table>

The above examples and results demonstrate the inventive delivery method using multi-point array ID administration and single needle ID administration results in more rapid uptake with higher C_{max} than SC injection. ID uptake and distribution is ostensibly unaffected by device geometry parameters, using needle lengths of about 0.3 to about 2.0mm, needle number and needle spacing. No concentration limit for biological absorption was found and PK profiles were dictated principally by the concentration-based delivery rate. The primary limitations of ID administration are the total volume and volumetric infusion-rate limits for leak-free instillation of exogenous substances into a dense tissue compartment. Since absorption of drugs from the ID space appears to be insensitive to both device design and volumetric infusion rate, numerous formulation/device combinations can be used to overcome these limitations and provide the required or desired therapeutic profiles. For example, volume limited dosing regimens can be circumvented either by using more concentrated formulations or increasing the total number of instillation sites. In addition, effective PK control is obtained by manipulating infusion or administration rate of substances.
[0089] In general, ID delivery as taught by the methods described hereto via dermal access devices provides a readily accessible and reproducible parenteral delivery route, with high bioavailability, as well as the ability to modulate plasma profiles by adjusting the device infusion parameters, since uptake is minimally rate-limited by biological uptake parameters.

[0090] In the previously described examples, the methods practiced by the invention demonstrate the ability to deliver a drug in vivo with greatly improved pharmacologically relevant rates. This data indicates an improved pharmacological result for ID administration as taught by the methods described of other drugs in humans would be expected according to the methods of the invention.

[0091] All references cited in this specification are hereby incorporated by reference. The discussion of the references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art relevant to patentability. Applicants reserve the right to challenge the accuracy and pertinency of the cited references.
WHAT IS CLAIMED IS:

1. A method for directly delivering a substance into an intradermal space within a mammal, the method comprising bolus administration of said substance into the dermis, whereby the administered substance has at least one improved pharmacokinetic parameter relative to the same pharmacokinetic parameter produced upon administration of the same substance subcutaneously.

2. The method of claim 1 wherein the administering is through at least one small gauge hollow needle.

3. The method of claim 1 wherein the needle has an outlet with an exposed height between 0 and 1 mm.

4. The method of Claim 1 wherein administering comprises inserting the needle to a depth which delivers the substance at least about 0.3 mm below the surface to no more than about 2 mm below the surface.

5. The method of Claim 4 wherein administering comprises inserting the needle into the skin to a depth of at least about 0.3 mm and no more than about 2 mm.

6. The method of claim 1 wherein the improved pharmacokinetics is a decrease in $T_{\text{max}}$.

7. The method of claim 1 wherein the improved pharmacokinetics is an increase in $C_{\text{max}}$.

8. The method of claim 1 wherein the improved pharmacokinetics is a decrease in $T_{\text{lag}}$. 
9. The method of claim 1 wherein the improved pharmacokinetics is an enhanced absorption rate.

10. The method of claim 1 wherein the substance is administered over a time period of not more than ten minutes.

11. The method of claim 1 wherein the substance is administered at a rate between 1 nL/min. and 200 mL/min.

12. The method of claim 1 wherein said substance is a hormone.

13. The method of claim 12 wherein the hormone is a growth hormone.

14. The method of claim 13 wherein the growth hormone is human growth hormone.

15. The method of claim 1 wherein the substance has a molecular weight greater than 1000 daltons.

16. The method of claim 1 wherein said substance is hydrophobic.

17. The method of claim 1 wherein said substance is hydrophilic.

18. The method of claim 1 wherein the needle(s) are inserted substantially perpendicularly to the skin.

19. A method of administering a pharmaceutical substance comprising administering the substance intradermally through one or more microneedles having a length and outlet suitable for selectively delivering the substance into the dermis over a time period of not more than ten minutes to obtain absorption of the substance in the dermis thereby producing improved systemic pharmacokinetics compared to subcutaneous administration.
20. The method of Claim 19 wherein the improved pharmacokinetics is decreased $T_{\text{max}}$.

21. The method of claim 19 wherein the improved pharmacokinetics is an increase in $C_{\text{max}}$.

22. The method of claim 19 wherein the improved pharmacokinetics is a decrease in $T_{\text{lag}}$.

23. The method of claim 19 wherein the improved pharmacokinetics is an enhanced absorption rate.

24. The method of claim 19 wherein the length of the microneedle is from about 0.3 mm to about 2.0 mm.

25. The method of Claim 19 wherein the microneedle is a 30 to 50 gauge needle.

26. The method of Claim 19 wherein the microneedle has an outlet of from 0 to 1 mm.

27. The method of Claim 19 wherein the microneedle is configured in a delivery device which positions the microneedle substantially perpendicular to skin surface.

28. The method of Claim 19 wherein the microneedle needle is contained in an array of microneedles.

29. The method of Claim 28 wherein the array comprises 3 microneedles.

30. The method of Claim 28 wherein the array comprises 6 microneedles.
31. A method for administering a macromolecular and/or hydrophobic pharmaceutical substance to a patient, the method comprising selective bolus delivery of the substance intradermally to achieve a substantially higher $C_{\text{max}}$ and/or a substantially shorter $T_{\text{max}}$ and/or a substantially shorter time to reach a threshold blood serum concentration for pharmaceutical effect of the substance, by comparison with subcutaneous administration of the substance at an identical dose and rate of delivery.

32. The method of claim 31 wherein selectively delivering the substance intradermally comprises selectively injecting the substance intradermally.

33. The method of claim 31 wherein administering comprises infusing the substance over a period of from about 2 min to about 10 min.

34. The method of claim 31 wherein administering comprises delivering a bolus of the substance over a period of less than 10 minutes.

35. The method of claim 31 wherein administering the substance intradermally comprises administering the substance through a needle having a length and outlet configuration which allows selective intradermal delivery of the substance.

36. The method of claim 35 wherein the microneedle has a length of from about 0.3 mm to about 2.0 mm.

37. The method of claim 35 wherein the microneedle is a 30 to 50 gauge needle.

38. The method of Claim 35 wherein the microneedle is configured in a delivery device which positions the microneedle substantially perpendicular to skin surface.

39. The method of Claim 35 wherein the microneedle needle is in an array of microneedles.
40. The method of Claim 39 wherein the array comprises 3 microneedles.

41. The method of Claim 39 wherein the array comprises 6 microneedles.

42. The method of claim 31 wherein the substance is administered at a volume rate of from about 2 microliters per minute to about 200 milliliters per minute.

43. The method of claim 42 wherein the substance is administered at a volume rate of from about 2 microliters per minute to about 10 milliliters per minute.

44. The method of claim 42 wherein the substance is administered at a volume rate of from about 10 microliters per minute to about 200 milliliters per minute.

45. The method of claim 31 wherein the substance comprises a polysaccharide.

46. The method of claim 31 wherein the substance comprises heparin molecule or a fragment thereof having anticoagulant activity.

47. The method of claim 31 wherein the substance comprises Fragmin®

48. The method of claim 31 wherein the substance comprises a protein.

49. The method of claim 31 wherein the protein comprises a human growth hormone.

50. The method of claim 31 wherein the substance comprises Genotropin®.

51. The method of claim 42 wherein the rate is constant, variable or combinations thereof.
52. The method of claim 31 wherein the substance comprises a pegylated protein.

53. A method for delivering a bioactive substance to a subject comprising: contacting the skin of the subject with a device having a dermal-access means for accurately targeting the dermal space of the subject with an efficacious amount of the bioactive substance and administering a bolus of the substance into the dermis, wherein the pharmacokinetics of the bioactive substance is improved relative to the pharmacokinetics of the substance when administered subcutaneously.

54. The method of claim 53 wherein the improved pharmacokinetics is a decrease in $T_{\text{max}}$.

55. The method of claim 53 wherein the improved pharmacokinetics comprises an increase in $C_{\text{max}}$ of the substance compared to subcutaneous injection.

56. The method of claim 53 wherein the improved pharmacokinetics is a decrease in $T_{\text{lag}}$.

57. The method of Claim 53 wherein the device has a fluid driving means including a syringe, infusion pump, piezoelectric pump, electromotive pump, electromagnetic pump, or Belleville spring.

58. The method of Claim 53 wherein the dermal access means comprises one or more hollow microcannula having a length of from about 0.3 to about 2.0mm.

59. The method of Claim 53 wherein said dermal access means comprises one or more hollow microcannula having an outlet with an exposed height between 0 and 1 mm.

60. A method for delivering a bioactive substance to a subject comprising: contacting the skin of a subject with a device having a dermal-access means for accurately targeting the dermal space of the subject with an efficacious amount of the
bioactive substance at a rate of 1nL/min. to 200 mL/ min. and delivering the substance into the dermis over a time period of not more than ten minutes; wherein the rapid onset pharmacokinetics of the bioactive substance is substantially improved relative to subcutaneous injection.

61. The method of claim 60 wherein the pharmokinetics is a decreased $T_{\text{max}}$.

62. The method of claim 60 wherein the pharmokinetics is an increased $C_{\text{max}}$.

63. The method of claim 60 wherein the pharmokinetics is a decreased $T_{\text{lag}}$.

64. The method of claim 60 wherein the pharmokinetics is an enhanced absorption rate.

65. The method of claim 60 wherein the dermal access means has one or more hollow microcannula that inserts into the skin of said subject to a depth of from about 0.3 to about 2.0 mm.

66. The method of claim 60 wherein the dermal access means has one or more hollow microcannula having an outlet with an exposed height between 0 and 1 mm.
Figure 9
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

<table>
<thead>
<tr>
<th>IPC</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 A61M37/00</td>
<td>A61M5/46</td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

<table>
<thead>
<tr>
<th>IPC</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 A61M</td>
<td>A61B</td>
</tr>
</tbody>
</table>

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 5 997 501 A (KELLY JOHN GERARD ET AL) 7 December 1999 (1999-12-07) abstract column 5, line 22-33 column 10, line 14-41; figures 1-4 column 17, line 30-35</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>US 5 820 622 A (KELLY JOHN GERARD ET AL) 13 October 1998 (1998-10-13) column 4, line 63 -column 6, line 40</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>EP 1 086 718 A (BECTON DICKINSON CO) 28 March 2001 (2001-03-28) abstract column 7, line 9 -column 8, line 49; figures 1-3A</td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

**Date of the actual completion of the international search**

26 August 2002

**Date of mailing of the international search report**

03/09/2002

**Name and mailing address of the ISA**

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx: 51 651 epos nl, Fax: (+31-70) 340-3016

**Authorized officer**

Jameson, P
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 00 67647 A (SCIMED LIFE SYSTEMS INC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>16 November 2000 (2000-11-16)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>page 3, line 5-15</td>
<td></td>
</tr>
<tr>
<td></td>
<td>page 12, line 8-29</td>
<td></td>
</tr>
<tr>
<td></td>
<td>abstract</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>WO 00 74763 A (GEORGIA TECH RES CORP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14 December 2000 (2000-12-14)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>page 8, line 3-14; figures 2,7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>abstract</td>
<td></td>
</tr>
</tbody>
</table>
INTERNATIONAL SEARCH REPORT

Box I  Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(e) for the following reasons:

1. ☒ Claims Nos.: 1–66  
   because they relate to subject matter not required to be searched by this Authority, namely:  
   Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

2. ☐ Claims Nos.:  
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:  
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II  Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest  
☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 5997501 A</td>
<td>07-12-1999</td>
<td>AT 220931 T</td>
<td>15-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1076395 A</td>
<td>06-06-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2176342 A1</td>
<td>26-05-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0729366 A1</td>
<td>04-09-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9513838 A1</td>
<td>26-05-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 111685 A</td>
<td>24-09-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 9504974 T</td>
<td>20-05-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 276485 A</td>
<td>24-11-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5527288 A</td>
<td>18-06-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5848991 A</td>
<td>15-12-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9409185 A</td>
<td>25-07-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 3753195 A</td>
<td>31-05-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9614292 A1</td>
<td>17-05-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5807375 A</td>
<td>15-09-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5800420 A</td>
<td>01-09-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2001149485 A</td>
<td>05-06-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4802100 A</td>
<td>21-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4978400 A</td>
<td>21-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1176914 A1</td>
<td>06-02-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1176918 A2</td>
<td>06-02-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0067646 A1</td>
<td>16-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0067647 A1</td>
<td>16-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0067655 A2</td>
<td>16-11-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6319230 B1</td>
<td>20-11-2001</td>
</tr>
<tr>
<td>WO 0074763 A</td>
<td>14-12-2000</td>
<td>AU 5461300 A</td>
<td>28-12-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1187653 A2</td>
<td>20-03-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0074763 A2</td>
<td>14-12-2000</td>
</tr>
</tbody>
</table>